Literature DB >> 8467108

Parenteral nutrition in hyperemesis gravidarum.

V Charlin1, L Borghesi, J Hasbún, R Von Mülenbrock, M I Moreno.   

Abstract

Hyperemesis gravidarum (HG) is a clinical condition that threatens fetal viability and even the mother's life when the severity of symptoms almost completely prevents the intake of food. Parenteral nutrition (PN) is a possible alternative. We present eight patients with HG. There were 10 PN treatments because two of the patients required the treatment twice. There were 9 central venous and 1 peripheral treatment delivery. The average age of the patients was 27.5 yr. Gestational ages varied from 8 to 19 wk. PN treatments were formulated as amino acid and glucose solutions (fat emulsions in 2 of the 8 cases) blended with vitamins and electrolytes. These treatments lasted 5-16 days. Before PN deliveries were initiated, five of the patients presented some degree of protein-calorie and/or visceral protein malnutrition. All of them showed minor liver dysfunction, which did not change during PN. Newborns were term deliveries, except for one case of missed abortion. Results show that PN constitutes a therapeutic alternative in cases of HG that do not respond to the standard treatment of parenteral hydration and antiemetics. In fact, symptoms disappear promptly, and no significant complications arise.

Entities:  

Mesh:

Year:  1993        PMID: 8467108

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  2 in total

Review 1.  Treatment of nausea and vomiting in pregnancy. When should it be treated and what can be safely taken?

Authors:  C Nelson-Piercy
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

2.  Nausea and vomiting of pregnancy in women with bulimia nervosa and eating disorders not otherwise specified.

Authors:  Leila Torgersen; Ann Von Holle; Ted Reichborn-Kjennerud; Cecilie Knoph Berg; Robert Hamer; Patrick Sullivan; Cynthia M Bulik
Journal:  Int J Eat Disord       Date:  2008-12       Impact factor: 4.861

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.